Home » QIDP Antibiotics » Page 15

Category Archives: QIDP Antibiotics

All AllPhasePharma blogs dealing predominantly with a QIDP antibiotic

A GO / NO GO decision:  Delafloxacin Stumbles in Gonorrhea Study

Posted on by — No Comments ↓

The treatment history of N. gonorrhoeae makes for fascinating reading.  This organism has always been able to keep the upper hand in the war of bug versus drug.  Once susceptible to sulfa drugs, to penicillin, tetracyclines and fluoroquinolones, it sequentially become resistant in the matter of a decade to every Continue reading A GO / NO GO decision:  Delafloxacin Stumbles in Gonorrhea Study→

Nominating Thiamphenicol for IDSA’s 10 x ’20 Campaign

Posted on by — No Comments ↓

If you were developing a new antibiotic with a novel MoA, one that covers most GPC, most GNR, most anaerobes and atypicals, including many MDR pathogens like MRSA, enterococci (both E. faecalis and E. faecium), and one that has also activity against rickettsiae and bioterrorism agents, you would consider it a Continue reading Nominating Thiamphenicol for IDSA’s 10 x ’20 Campaign→

The Circuitous Route to Phase 3:  Another Chapter in the Fitful Development of PTK-0796

Posted on by — No Comments ↓

When antibiotics change hands, it can be a good thing.  Small companies are often desperate to attract a partner with ‘deep pockets’ to help them finance an expensive late phase development but often have to give up control once the honeymoon period is over.  Such transitions can bring delays because new Continue reading The Circuitous Route to Phase 3:  Another Chapter in the Fitful Development of PTK-0796→